Trends in the survival of patients diagnosed with kidney or urinary bladder cancer in the Nordic countries 1964-2003 followed up to the end of 2006
Trends in the survival of patients diagnosed with kidney or urinary bladder cancer in the Nordic countries 1964-2003 followed up to the end of 2006
复制标题
DOI：
10.3109/02841860903575299
复制
发表时间：
2010-06-01
期刊：
影响因子：
3.1
通讯作者：
Storm, Hans H.
中科院分区：
文献类型：
--
作者：
Engholm, Gerda;Hakulinen, Timo;Storm, Hans H.
背景先前的研究表明，北欧国家在肾癌或膀胱癌诊断后基于人群的相对生存率方面存在系统性差异。随着时间的推移和北欧登记处之间的膀胱癌的比较是复杂的变量编码的做法方面纳入原位病例浸润性肿瘤。材料和方法。研究了1964-2003年在北欧国家诊断为泌尿系癌症并随访至2006年死亡的患者的5年相对生存率，并与发病率和死亡率的发展进行了对比。结果膀胱癌后的存活率高于肾癌，男性最高。多年来，所有国家的生存率都有所提高，肾癌的生存率高于膀胱癌。丹麦肾癌患者的增长率多年来一直低于其他国家，特别是妇女，导致1999-2003年丹麦的存活率比其他国家低10-20%。丹麦膀胱癌患者的生存率在最后一个时期比其他北欧国家的男性低4%，女性低10%。差异主要出现在诊断后的第一年，在丹麦观察到较高的超额死亡率。随着诊断时年龄的增加，生存率下降。结论在所有北欧国家，肾癌和膀胱癌的5年相对生存率都在增加，这是有希望的，但对于肾癌，在其他疾病的成像研究期间偶然检测到的较高百分比可能起作用。丹麦的生存率最低，尽管他们的做法包括良性条件与浸润性膀胱癌。丹麦肾癌和膀胱癌患者在确诊后第一年的生存率较低可能是由于平均诊断较晚，吸烟相关疾病的合并症较高，以及丹麦的癌症治疗和管理不足。
Background. Previous studies have shown systematic differences between the Nordic Countries in population-based relative survival following a kidney or urinary bladder cancer diagnosis. Comparison of bladder cancer over time and between Nordic registries is complicated by variable coding practices with respect to the inclusion of in situ cases with invasive tumours. Material and methods. Five-year relative survival of patients with urinary cancer diagnosed in the Nordic countries 1964-2003 and followed up for death through 2006 was studied and contrasted with developments in incidence and mortality. Results. The survival following bladder cancer was higher than for kidney cancer and highest for men. Survival increased over the years in all countries, more for kidney cancer than bladder cancer. For Danish kidney cancer patients, the rate of increase over all the years has been lower than in the other countries, especially among women, resulting in a survival in Denmark some 10-20% points lower than elsewhere in 1999-2003. Danish bladder cancer patient survival was in the last period 4% points lower among men and 10% points lower among women than in the other Nordic countries. The differences were mainly found in the first year following diagnosis, where a higher excess mortality in Denmark was observed. Survival decreased with higher age at diagnosis. Conclusion. The increasing 5-year relative survival in all the Nordic countries for both kidney and bladder cancer are promising, but for kidney cancer a higher percentage detected coincidentally during an imaging investigation for other diseases could play a role. Denmark had the lowest survival, despite their known practice of including benign conditions with invasive bladder cancers. The lower Danish survival after kidney and bladder cancer in the first year after diagnosis could be due to later diagnosis on average, a higher co-morbidity from smoking-related diseases, and perhaps, less adequate cancer treatment and management in Denmark.